Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT. Keegan NM, et al. Among authors: furney sj. Cancers (Basel). 2021 Mar 11;13(6):1225. doi: 10.3390/cancers13061225. Cancers (Basel). 2021. PMID: 33799597 Free PMC article.
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ. Toomey S, et al. Among authors: furney sj. Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782. Oncotarget. 2016. PMID: 27776352 Free PMC article.
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A. Elster N, et al. Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30023006 Free PMC article.
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S. Coté D, et al. PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018. PLoS One. 2018. PMID: 30071039 Free PMC article. Clinical Trial.
Mucinous adenocarcinoma of the colon and rectum: A genomic analysis.
Reynolds IS, O'Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Furney SJ, Burke JP. Reynolds IS, et al. Among authors: furney sj. J Surg Oncol. 2019 Dec;120(8):1427-1435. doi: 10.1002/jso.25764. Epub 2019 Nov 14. J Surg Oncol. 2019. PMID: 31729037
Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Toomey S, Gunther J, Carr A, Weksberg DC, Thomas V, Salvucci M, Bacon O, Sherif EM, Fay J, Kay EW, Sheehan KM, McNamara DA, Sanders KL, Mathew G, Breathnach OS, Grogan L, Morris PG, Foo WC, You YN, Prehn JH, O'Neill B, Krishnan S, Hennessy BT, Furney SJ. Toomey S, et al. Among authors: furney sj. Cancers (Basel). 2020 Jul 6;12(7):1808. doi: 10.3390/cancers12071808. Cancers (Basel). 2020. PMID: 32640573 Free PMC article.
61 results